AL001
Bipolar Disorder
Key Facts
About Alzamend Neuro
Alzamend Neuro is a clinical-stage biotech focused on developing novel therapeutics for Alzheimer's disease, bipolar disorder, MDD, and PTSD. Its strategy leverages two licensed technology platforms: an ionic cocrystal for improved lithium delivery (AL001) and a cell-based immunotherapeutic vaccine for Alzheimer's (ALZN002). Key recent achievements include initiating a Phase II trial for AL001 in bipolar disorder with Massachusetts General Hospital and completing a $5 million private placement. The company operates as a lean, development-focused entity targeting significant unmet needs in large patient populations.
View full company profileAbout Alzamend Neuro
Alzamend Neuro is a clinical-stage biotech focused on developing novel therapeutics for Alzheimer's disease, bipolar disorder, MDD, and PTSD. Its strategy leverages two licensed technology platforms: an ionic cocrystal for improved lithium delivery (AL001) and a cell-based immunotherapeutic vaccine for Alzheimer's (ALZN002). Key recent achievements include initiating a Phase II trial for AL001 in bipolar disorder with Massachusetts General Hospital and completing a $5 million private placement. The company operates as a lean, development-focused entity targeting significant unmet needs in large patient populations.
View full company profileAbout Alzamend Neuro
Alzamend Neuro is a clinical-stage biotech focused on developing novel therapeutics for Alzheimer's disease, bipolar disorder, MDD, and PTSD. Its strategy leverages two licensed technology platforms: an ionic cocrystal for improved lithium delivery (AL001) and a cell-based immunotherapeutic vaccine for Alzheimer's (ALZN002). Key recent achievements include initiating a Phase II trial for AL001 in bipolar disorder with Massachusetts General Hospital and completing a $5 million private placement. The company operates as a lean, development-focused entity targeting significant unmet needs in large patient populations.
View full company profileAbout Alzamend Neuro
Alzamend Neuro is a clinical-stage biotech focused on developing novel therapeutics for Alzheimer's disease, bipolar disorder, MDD, and PTSD. Its strategy leverages two licensed technology platforms: an ionic cocrystal for improved lithium delivery (AL001) and a cell-based immunotherapeutic vaccine for Alzheimer's (ALZN002). Key recent achievements include initiating a Phase II trial for AL001 in bipolar disorder with Massachusetts General Hospital and completing a $5 million private placement. The company operates as a lean, development-focused entity targeting significant unmet needs in large patient populations.
View full company profileAbout Alector
Alector is a clinical-stage biotech company with a mission to conquer neurodegenerative diseases by modulating the immune system. Its strategy is validated by major partnerships with GSK and AbbVie, and it is advancing a late-stage pipeline led by latozinemab in Phase 3 for frontotemporal dementia. The company's proprietary Alector Brain Carrier (ABC) platform aims to solve the critical challenge of blood-brain barrier delivery, positioning it at the forefront of a novel therapeutic paradigm.
View full company profileTherapeutic Areas
Other Bipolar Disorder Drugs
| Drug | Company | Phase |
|---|---|---|
| Undisclosed Programs | johnson-and-johnson-innovative-medicine | Pipeline |
| ALM008 | Almatica Pharma | Phase 2 |
| 4MT2001 | 4M Therapeutics | Pre-clinical |
| Bipolar Disorder Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| RAP-219 | Rapport Therapeutics | Discovery |